LWM
CTMX icon

Liberty Wealth Management’s CytomX Therapeutics CTMX Stock Holding History

Liberty Wealth Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$3K – 362
2021
Q3 		$3K Hold
500
– – ﹤0.01% 1010
2021
Q2 		$3K Hold
500
– – ﹤0.01% 863
2021
Q1 		$3K Hold
500
– – ﹤0.01% 764
2020
Q4 		$3K Hold
500
– – ﹤0.01% 760
2020
Q3 		$3K Buy
500
+150
+43% +$1.11K ﹤0.01% 699
2020
Q2 		$3K Hold
350
– – ﹤0.01% 688
2020
Q1 		$3K Hold
350
– – ﹤0.01% 664
2019
Q4 		$3K Hold
350
– – ﹤0.01% 723
2019
Q3 		$3K Buy
+350
New +$3.45K ﹤0.01% 701

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Liberty Wealth Management's CTMX Position: Q4 2021 in Review

Liberty Wealth Management sold out of CytomX Therapeutics (CTMX) in Q4 2021, closing a stake of 500 shares — an estimated $3K sold.

Liberty Wealth Management first reported a position in CTMX in Q3 2019 and held it in 9 quarters. The position peaked at $3K in Q3 2021. 110 funds tracked by Wall St. Rank hold CTMX as of Q4 2021.

  • Liberty Wealth Management reported no remaining CytomX Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Liberty Wealth Management sold 500 CytomX Therapeutics shares in Q4 2021, an estimated $3K.
  • Liberty Wealth Management first reported a position in CytomX Therapeutics in Q3 2019 and held it in 9 quarters.
  • Liberty Wealth Management's CytomX Therapeutics position peaked at $3K in Q3 2021.
  • 110 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2021.

Based on Liberty Wealth Management's 13F filing for Q4 2021, filed 15 Feb 2022.